| Literature DB >> 32064572 |
Howeida Abdullah Mustafa1,2, Afraa Mohamed Suliman Albkrye3, Buthiena Mohamed AbdAlla3,4, Mona AbdelRahman Mohammed Khair3, Nidal Abdelwahid3, Hind Abdelaziz Elnasri3.
Abstract
BACKGROUND: The Peroxisome proliferator-activated receptor gamma gene (PPARG), encodes a member of the peroxisome-activated receptor subfamily of nuclear receptors. PPARs form heterodimers with retinoid X receptors (RXRs) which regulate transcription of various genes. Three subtypes of PPARs are known: PPAR-alpha, PPAR-delta and PPAR-gamma. The protein encoded by this gene is PPAR-gamma which is a regulator of adipocyte differentiation. PPARG-gamma has been implicated in the pathology of numerous diseases including obesity, diabetes, atherosclerosis and cancer. AIM: This study aimed to perform insilico analysis to predict the effects that can be imposed by SNPs reported in PPARG gene.Entities:
Keywords: Diabetes insilico; PPARG; Polyphen; SIFT; SNP
Year: 2020 PMID: 32064572 PMCID: PMC7024687 DOI: 10.1186/s40169-020-0258-1
Source DB: PubMed Journal: Clin Transl Med
Fig. 1Genes cogene-expressed with PPARG gene
Genes co-expressed and sharing a domain with PPARG
| Gene Symbol | Description | Co-expression | Shared domain |
|---|---|---|---|
| RXRA | Retinoid X receptor alpha | Yes | Yes |
| SAT1 | Spermidine/spermine N1-acetyltransferase 1 | No | No |
| PTGER2 | Prostaglandin E receptor 2 | No | No |
| ACAA1 | Acetyl-CoA acyltransferase 1 | No | No |
| NCOA6 | Nuclear receptor coactivator 6 | No | No |
| RXRB | Retinoid X receptor beta | Yes | Yes |
| AQP7 | Aquaporin 7 | Yes | No |
| UGT1A10 | UDP Glucuronosyltransferase family1 member | No | No |
| NCOA4 | Nuclear receptor coactivator 4 | No | No |
| GK2 | Glycerol kinase 2 | No | No |
| CHD7 | Chromodomain helicase DNA binding protein 7 | No | No |
| SETDB1 | SET Domain bifurcated 1 | No | No |
| CD83 | CD83 Molecule | No | No |
| SLC27A1 | Solute carrier family 27 member 1 | No | No |
| LIPA | Lipase A, lysosomal acid type | No | No |
| SLC27A4 | Solute carrier family 27 member 4 | No | No |
| SCD5 | Stearoyl-CoA desaturase 5 | No | No |
| DBI | Diazepam binding inhibitor, acyl-CoA binding protein | No | No |
| FABP4 | Fatty acid binding protein 4 | Yes | No |
| NCOA1 | Nuclear receptor coactivator 1 | No | No |
PPARG functions and its appearance in network and genome
| Function | FDR | Coverage | |
|---|---|---|---|
| Genes in network | Genes in genome | ||
| Nuclear hormone receptor binding | 6.81 E–4 | 5 | 94 |
| Hormone receptor binding | 6.81 E–4 | 5 | 103 |
| Transcription co-activator activity | 1.20 E–3 | 6 | 249 |
| Intracellular receptor signaling pathway | 1.09 E–2 | 5 | 207 |
| Long chain fatty acid transport | 2.03 E–2 | 3 | 33 |
| Ligand activated sequence-specific DNA binding RNA polymerase II transcription factor activity | 2.03 E–2 | 3 | 44 |
| Direct ligand regulated sequence-specific DNA binding transcription factor activity | 2.08 E–2 | 3 | 36 |
| Ligand-dependent nuclear receptor transcription co-activator activity | 2.51 E–2 | 3 | 40 |
| Fatty acid transport | 3.19 E–2 | 3 | 45 |
| Steroid hormone receptor binding | 6.85 E–2 | 3 | 60 |
| Transcription initiation from RNA Polymerase II Promotor | 8.00 E–2 | 4 | 190 |
| Peroxisome proliferator activated receptor signaling pathway | 8.00 E–2 | 2 | 10 |
Nonsynonymous SNPs predicted with SIFT, Polyphen, I-Mutant and PHD-SNP programs, chosen SNPs with PSIC SD range (1–0.99) and Tolerance Index equal (0.009)
| SNP ID | Protein ID | Amino acid change | SIFT | Polyphen | I Mutant | ||||
|---|---|---|---|---|---|---|---|---|---|
| SIFT prediction | SIFT score | Polyphen prediction | Polyphen score | SVM2 prediction effect | DDG | RI | |||
| rs72551364 | ENSP00000287820 | R425C | Deleterious | 0 | Probably damaging | 1 | Decrease | − 2.38 | 7 |
| rs72551364 | ENSP00000312472 | R397C | Deleterious | 0 | Probably damaging | 1 | Decrease | − 0.67 | 7 |
| rs72551364 | ENSP00000380205 | R397C | Deleterious | 0 | Probably damaging. | 1 | Decrease | − 0.67 | 7 |
| rs72551364 | ENSP00000380207 | R397C | Deleterious | 0 | Probably damaging | 1 | Decrease | − 0.67 | 7 |
| rs72551364 | ENSP00000380210 | R397C | Deleterious | 0 | Probably damaging | 1 | Decrease | − 0.67 | 7 |
| rs72551364 | ENSP00000380221 | R403C | Deleterious | 0 | Benign | 0.356 | Decrease | − 0.85 | 7 |
| rs121909244 | ENSP00000287820 | P495L | Deleterious | 0.001 | Benign | 0.356 | Decrease | − 0.19 | 4 |
| rs121909244 | ENSP00000312472 | P467L | Deleterious | 0.001 | Probably damaging | 1 | Decrease | − 0.14 | 4 |
| rs121909244 | ENSP00000380205 | P467L | Deleterious | 0.001 | Probably damaging | 1 | Decrease | − 0.14 | 4 |
| rs121909244 | ENSP00000380207 | P467L | Deleterious | 0.001 | Probably damaging | 1 | Decrease | − 0.14 | 4 |
| rs121909244 | ENSP00000380210 | P467L | Deleterious | 0.001 | Probably damaging | 1 | Decrease | − 0.14 | 4 |
| rs121909244 | ENSP00000380221 | P473L | Deleterious | 0.001 | Probably damaging | 1 | Decrease | 0.46 | 4 |
Nonsynonymous SNPs predicted with PHD-SNPs & SNPs & Go programs, chosen SNPs with PSIC SD range (1–099) and tolerance index equal (0.009)
| SNP ID | Protein ID | Amino acid change | PHD-SNPs | SNPs & Go | ||
|---|---|---|---|---|---|---|
| PHD-SNP effect | RI | SNPs & Go prediction | RI | |||
| rs72551364 | ENSP00000287820 | R425C | Disease | 7 | Disease | 6 |
| rs72551364 | ENSP00000312472 | R397C | Disease | 7 | Disease | 6 |
| rs72551364 | ENSP00000380205 | R397C | Disease | 7 | Disease | 6 |
| rs72551364 | ENSP00000380207 | R397C | Disease | 7 | Disease | 6 |
| rs72551364 | ENSP00000380210 | R397C | Disease | 7 | Disease | 6 |
| rs72551364 | ENSP00000380221 | R403C | Disease | 7 | Disease | 6 |
| rs121909244 | ENSP00000287820 | P495L | Disease | 4 | Disease | 5 |
| rs121909244 | ENSP00000312472 | P467L | Disease | 4 | Disease | 5 |
| rs121909244 | ENSP00000380205 | P467L | Disease | 4 | Disease | 5 |
| rs121909244 | ENSP00000380207 | P467L | Disease | 4 | Disease | 5 |
| rs121909244 | ENSP00000380210 | P467L | Disease | 4 | Disease | 5 |
| rs121909244 | ENSP00000380221 | P473L | Disease | 4 | Disease | 5 |
Fig. 23D model by Chimera and Project HOPE for PPARG protein